Immunologically defined prognostic subgroups as predictors of response to BCG immunotherapy

Recent Results Cancer Res. 1982:80:219-26. doi: 10.1007/978-3-642-81685-7_35.


Fifty-two stage I and II patients with nonsmall cell lung cancer were randomized after resection to no further therapy, BCG, or BCG plus allogeneic tumor cells. Patients have been observed for 16-65 months (mean 39.5). When the two immunotherapy arms were combined and plotted against controls, trend analysis suggested (P = 0.088) an increase in disease-free interval (DFI) only for stage I patients. The one-way mixed lymphocyte culture (MLC) values were depressed in some patients prior to any immune stimulation. Immunotherapy significantly benefited DFI among patients with a depressed MLC.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Clinical Trials as Topic
  • Follow-Up Studies
  • Humans
  • Immunotherapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / therapy*
  • Lymphocytes / immunology
  • Mycobacterium bovis / immunology
  • Neoplasm Staging
  • Prognosis